Who are Augmenting: Antidepressant + Aripiprazole's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/augmenting-antidepressant-aripiprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Augmenting: Antidepressant + Aripiprazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Augmenting: Antidepressant + Aripiprazole (Augmenting: Antidepressant + Aripiprazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic (augmentation agent). Area: Psychiatry / Mental Health.

phase 3 Atypical antipsychotic (augmentation agent) Dopamine D2 receptor (partial agonist), Serotonin 5-HT1A receptor Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Augmenting: Antidepressant + Aripiprazole (Augmenting: Antidepressant + Aripiprazole) — VA Office of Research and Development. Aripiprazole augments antidepressant therapy by acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, enhancing monoaminergic neurotransmission in depression.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Augmenting: Antidepressant + Aripiprazole TARGET	Augmenting: Antidepressant + Aripiprazole	VA Office of Research and Development	phase 3	Atypical antipsychotic (augmentation agent)	Dopamine D2 receptor (partial agonist), Serotonin 5-HT1A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic (augmentation agent) class)

VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Augmenting: Antidepressant + Aripiprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/augmenting-antidepressant-aripiprazole. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing